

Tilman TodenhÄ¶fer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9303733/publications.pdf>

Version: 2024-02-01

24
papers

1,026
citations

758635

12
h-index

713013

21
g-index

25
all docs

25
docs citations

25
times ranked

1932
citing authors

#	ARTICLE	IF	CITATIONS
1	Receptor Activator of NF Kappa B (RANK) Expression Indicates Favorable Prognosis in Patients with Muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2022, 8, 718-727.	1.6	0
2	Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer. <i>World Journal of Men's Health</i> , 2021, 39, 38.	1.7	2
3	Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB. <i>World Journal of Urology</i> , 2021, 39, 2953-2960.	1.2	5
4	Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 498.e1-498.e11.	0.8	3
5	Comparison of the metabolome in urine prior and eight weeks after radical prostatectomy uncovers pathologic and molecular features of prostate cancer. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 205, 114288.	1.4	3
6	Re: Aurélien Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>Eur Urol</i> 2020;77:420-433. <i>European Urology</i> , 2020, 77, e105-e106.	0.9	29
7	Prognostic impact of somatostatin receptor expression in advanced bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 935.e17-935.e28.	0.8	3
8	Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review. <i>World Journal of Men's Health</i> , 2020, 38, 151.	1.7	7
9	Editorial Comment. <i>Journal of Urology</i> , 2020, 204, 77-77.	0.2	0
10	Editorial Comment. <i>Journal of Urology</i> , 2020, 203, 81-81.	0.2	0
11	Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer. <i>Disease Markers</i> , 2019, 2019, 1-8.	0.6	1
12	Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 12.	0.8	5
13	Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer. <i>BJU International</i> , 2018, 122, 152-159.	1.3	21
14	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2746-2755.	1.9	53
15	Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases. <i>Disease Markers</i> , 2018, 2018, 1-5.	0.6	9
16	Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?. <i>Disease Markers</i> , 2018, 2018, 1-5.	0.6	19
17	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 544-554.	0.9	638
18	An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. <i>European Urology</i> , 2017, 72, 142-150.	0.9	38

#	ARTICLE	IF	CITATIONS
19	Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 677-685.	1.2	16
20	Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-9.	0.6	28
21	High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients. <i>BMC Cancer</i> , 2014, 14, 649.	1.1	65
22	Stepwise Application of Urine Markers to Detect Tumor Recurrence in Patients Undergoing Surveillance for Non-Muscle-Invasive Bladder Cancer. <i>Disease Markers</i> , 2014, 2014, 1-7.	0.6	19
23	Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1148-1154.	0.8	27
24	Influence of Urinary Tract Instrumentation and Inflammation on the Performance of Urine Markers for the Detection of Bladder Cancer. <i>Urology</i> , 2012, 79, 620-625.	0.5	35